Enveric Biosciences Files Definitive Proxy Statement

TL;DR

Enveric Bio (ENVB) proxy statement filed. Annual meeting details out.

AI Summary

Enveric Biosciences, Inc. filed its definitive proxy statement on December 18, 2024, for its annual meeting. The company, previously known as Ameri Holdings, Inc. and Spatializer Audio Laboratories Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. The filing fee was not required.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming annual meeting, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing, not indicating immediate operational or financial risk.

Key Numbers

• 20241218 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• Enveric Biosciences, Inc. (company) — Registrant
• AMERI Holdings, Inc. (company) — Former Company Name
• SPATIALIZER AUDIO LABORATORIES INC (company) — Former Company Name
• 0001493152-24-050536 (dollar_amount) — Accession Number

FAQ

Key Financial Figures

• $0.01 — and outstanding common stock, par value $0.01 per share (“ Common Stock ”
• $10,600 — he solicitation of proxies for a fee of $10,600, plus reimbursement of expenses. In add
• $1.00 — intained a minimum closing bid price of $1.00 per share (the “ Minimum Bid Pric
• $5,000,000 m — sion because it did not comply with the $5,000,000 minimum stockholders’ equity initia

Filing Documents

• formdef14a.htm (DEF 14A) — 272KB
• proxy_001.jpg (GRAPHIC) — 3113KB
• proxy_002.jpg (GRAPHIC) — 762KB
• 0001493152-24-050536.txt ( ) — 5607KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 17 Other Matters 18 Deadline for Receipt of Stockholder Proposals 19 Stockholders Sharing the Same Address 19 Annex A - Reverse Stock Split Charter Amendment A-1 i ENVERIC BIOSCIENCES, INC. 4851 Tamiami Trail N., Suite 200 Naples, FL 34103 PROXY FOR SPECIAL MEETING OF STOCKHOLDERS To Be Held on January 17, 2025 Unless the context otherwise requires, references in this proxy statement to “ we ,” “ us ,” “ our ,” the “ Company ” or “ Enveric ” refer to Enveric Biosciences, Inc., a Delaware corporation and its consolidated subsidiary as a whole. In addition, unless the context otherwise requires, references to “stockholders” are to the holders of our common stock, par value $0.01 per share (“ Common Stock ”). The accompanying proxy is solicited by the Board of Directors (the “ Board ”) on behalf of Enveric Biosciences, Inc. to be voted at the Company’s Special Meeting of Stockholders (the “ Special Meeting ”) to be held on January 17, 2025, and at any adjournment, continuation or postponement thereof, for the purposes set forth in the accompanying Notice of Special Meeting of Stockholders (the “ Notice ”). The Special Meeting will be held virtually via a live webcast on the Internet on www.virtualshareholdermeeting.com/ENVB2025SM at 10:00 a.m. Eastern time. This proxy statement and accompanying form of proxy are dated December 18, 2024 and are expected to be first sent or given to stockholders on or about December 18, 2024. The executive offices of the Company are located at, and the mailing address of the Company is, 4851 Tamiami Trail N., Suite 200, Naples, FL 34103. The Company will pay the costs of soliciting proxies from stockholders. We have retained Kingsdale Advisors to assist in the solicitation of proxies for a fee of $10,600,

View Full Filing

View this DEF 14A filing on SEC EDGAR